表紙
市場調査レポート

アジア太平洋地域の乳がん治療薬市場の将来展望:新規のHER-2陽性治療法による、治療オプションの多様化

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

発行 GBI Research 商品コード 302278
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
アジア太平洋地域の乳がん治療薬市場の将来展望:新規のHER-2陽性治療法による、治療オプションの多様化 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
出版日: 2014年05月12日 ページ情報: 英文
概要

アジア太平洋地域諸国(インド・オーストラリア・中国・日本)の乳がん治療薬の市場は、2013年には15億米ドル、2020年には25億米ドルと予測されています。また、その間の年平均成長率(CAGR)は7.6%と推計されています。国別に見ると、2013年段階で日本が最大の8億7200万米ドル、中国が3億2000万米ドル、オーストラリアが2億3400万米ドル、インドが8100万米ドルとなっています。現在、HER-2遺伝子を標的とする治療薬を初め、多くの治療薬の開発が進展しています。治験中の分子612種類のうち、治験前および第I相にあるのが42%、第II相が16%、第III相が8%となっています。

当レポートでは、アジア太平洋地域諸国における乳がん治療法の関連市場について分析し、疾患の概要や主な治療パターン、上市済み製品の概要(安全性・効能など)、現在開発中の治療薬のパイプライン情報、地域全体および主要国における市場動向の見通し(今後8年間の予測値)、資本取引・事業提携の動きなどを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

  • 乳がん
  • 症状
  • 疫学
  • 病態生理
  • 診断
  • 予後と病期:分類法
  • 治療オプション
    • 外科手術および放射線治療
    • 化学療法
    • ホルモン療法
    • 標的療法
    • 薬物療法への抵抗性
    • 治療のガイドライン
    • 治療の有効性の計測

第3章 上市済み製品

  • 主な上市済み製品
    • ハーセプチン
    • ハラヴェン
    • アバスチン
    • ジェムザール
    • タキソテール
    • タイケルブ
    • フェマラ
    • アロマシン
    • ゾラデックス
    • アリミデックス
  • 上市済み製品のヒートマップ(効能・安全性の比較分析)

第4章 パイプライン分析

  • パイプラインの全体的状況
  • 分子種類別の分析
  • 機能メカニズム別の分析
  • 治験の失敗率
  • 治験の規模
  • 治験期間
  • パイプライン上の有望な候補薬
    • Buparlisib
    • Palbociclib
    • Afatinib dimaleate
    • Entinostat
    • Neratinib
    • BMN-673
    • Etirinotecan pegol

第5章 市場動向の予測(今後8年間分)

  • アジア太平洋地域市場
    • 治療法の利用パターン
    • 年間治療費
    • 市場規模
  • インド
  • オーストラリア
  • 中国
  • 日本
  • 市場促進・阻害要因

第6章 資本取引・戦略的企業提携の動き

  • ライセンス契約
  • 共同開発契約

第7章 付録

図表一覧

目次
Product Code: GBIHC331MR

GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes -

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the APAC breast cancer market from 2013 to 2020
  • Major marketed products in the APAC region along with a heat map of product performance
  • In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

  • The report will enhance your decision-making capability by allowing you to -
  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region's breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts business intelligence provider GBI Research.

According to the company's latest report*, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

Saurabh Sharma, Analyst for GBI Research, says: "The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab."

These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer's palbociclib and neratinib, and Boehringer Ingelheim's afatinib, will also contribute.

Sharma continues: "The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies."

From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to GBI Research.

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

This report analyzes treatment usage patterns, market characterization, pipeline analysis, key licensing and co-development deals in the breast cancer therapeutics market in Australia, China, India and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction

  • 2.1. Breast Cancer
  • 2.2. Symptoms
  • 2.3. Epidemiology
  • 2.4. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Prognosis and Disease Staging
    • 2.6.1. Classification
  • 2.7. Treatment Options
    • 2.7.1. Surgery and Radiation Therapy
    • 2.7.2. Chemotherapy
    • 2.7.3. Hormonal Therapies
    • 2.7.4. Targeted Therapies
    • 2.7.5. Resistance to Pharmacological Therapies
    • 2.7.6. Treatment Guidelines
    • 2.7.7. Measuring the Effectiveness of Treatment

3. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Marketed Products

  • 3.1. Key Marketed Products
    • 3.1.1. Herceptin
    • 3.1.2. Halaven
    • 3.1.3. Avastin
    • 3.1.4. Gemzar
    • 3.1.5. Taxotere
    • 3.1.6. Tykerb
    • 3.1.7. Femara
    • 3.1.8. Aromasin
    • 3.1.9. Zoladex
    • 3.1.10. Arimidex
  • 3.2. Heat Map for Marketed Products

4. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Pipeline Analysis

  • 4.1. Overall Pipeline
  • 4.2. Pipeline Analysis by Molecule Type
  • 4.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Clinical Trials - Failure Rate
  • 4.5. Clinical Trial Size
  • 4.6. Duration
  • 4.7. Promising Drug Candidates in Pipeline
    • 4.7.1. Buparlisib
    • 4.7.2. Palbociclib
    • 4.7.3. Afatinib dimaleate
    • 4.7.4. Entinostat
    • 4.7.5. Neratinib
    • 4.7.6. BMN-673
    • 4.7.7. Etirinotecan pegol

5. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020

  • 5.1. Asia-Pacific Market
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Market Size
  • 5.2. India
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Australia
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. China
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Deals and Strategic Consolidations

  • 6.1. Licensing Agreements
    • 6.1.1. Major Licensing Deals
  • 6.2. Co-development Agreements
    • 6.2.1. Major Co-development Agreements

7. Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-Filed and Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Pre-Registration
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Asia-Pacific
    • 7.2.2. India
    • 7.2.3. Australia
    • 7.2.4. China
    • 7.2.5. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. References
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
  • Table 2: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013
  • Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013
  • Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013
  • Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013
  • Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013
  • Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013
  • Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013
  • Table 9: Market for Breast Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013-2020
  • Table 10: Market for Breast Cancer Therapeutics, India, Forecast Data, 2013-2020
  • Table 11: Market for Breast Cancer Therapeutics, Australia, Forecast Data, 2013-2020
  • Table 12: Market for Breast Cancer Therapeutics, China, Forecast Data, 2013-2020
  • Table 13: Market for Breast Cancer Therapeutics, Japan, Forecast Data, 2013-2020

List of Figures

  • Figure 1: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013
  • Figure 2: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013
  • Figure 3: Breast Cancer Therapeutics Market, Global, Heat Map (Marketed Products)
  • Figure 4: Breast Cancer Therapeutics Market, Global, Pipeline by Stage of Development and Program Type, 2013
  • Figure 5: Breast Cancer Therapeutics Market, Global, Pipeline by Molecule Type and Stage of Development, 2013
  • Figure 6: Breast Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2013
  • Figure 7: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2013
  • Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Size (Participants), 2013
  • Figure 9: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration (months), 2013
  • Figure 10: Breast Cancer Therapeutics Market, Market Size ($m), 2013-2020
  • Figure 11: Breast Cancer Therapeutics Market, India, Market Size ($m), 2013-2020
  • Figure 12: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2013-2020
  • Figure 13: Breast Cancer Therapeutics Market, China, Market Size ($m), 2013-2020
  • Figure 14: Breast Cancer Therapeutics Market, Japan, Market Size ($m), 2013-2020
  • Figure 15: Breast Cancer Therapeutics Market, Global, Licensing Agreements, 2006-2013
  • Figure 16: Breast Cancer Therapeutics in APAC Market to 2020, Global, Licensing Agreements, 2006-2013
  • Figure 17: Breast Cancer Therapeutics in APAC Market to 2019, Global, Licensing Agreements, 2006-2013
  • Figure 18: Breast Cancer Therapeutics APAC Market to 2019, Global, Co-Development Deals, 2006-2013
  • Figure 19: Breast Cancer in APAC Market to 2019, Global, Co-Development Agreements, 2006-2013
  • Figure 20: GBI Research Market Forecasting Model
Back to Top